Synthetic biology, dual-use research, and the illusion of biodefense
The first part of this post is AI (Google Gemini) summarizing an article written by Jessica Rose. The second part of this post is the actual article itself. It strikes me as a good idea to have AI summarize things first, providing a rough frame of reference before reading the actual article itself, where one can immerse themselves in all the gritty details thereof.
---------------------------------------------
This document, titled "From Baric's blueprint to SV40 and back again" by Jessica Rose (dated May 28, 2026), is an analytical and critical essay. It argues that synthetic biology and dual-use biodefense research have crossed into dangerous territory, using Ralph Baric's research on coronavirus reverse genetics and the manufacturing process of COVID-19 mRNA vaccines as key examples.
Key Themes and Arguments
Synthetic Viral Genomics & Dual-Use Research:
The essay analyzes Ralph Baric’s 2007 paper on synthetic viral genomics, which demonstrated how coronaviruses could be reconstructed de novo from published sequence data alone.
The author argues this work serves as a blueprint for dual-use research—where technologies developed for biodefense and pandemic preparedness can easily be applied to engineer enhanced pathogens or potential biological weapons.
SV40 Sequences in mRNA Vaccines:
The author highlights the discovery of residual plasmid DNA—specifically SV40 promoter-enhancer-origin sequences—in Pfizer's commercial COVID-19 mRNA vials.
It explains that Pfizer switched from a PCR-amplified template (Process 1) to a plasmid-based system (Process 2) derived from standard pcDNA3.1 vectors grown in E. coli to scale up production.
The text asserts that these mammalian regulatory elements were retained purely as legacy manufacturing tools, were never intended for human injection, and pose theoretical risks such as insertional mutagenesis or altered gene expression.
Regulatory Omissions and Transparency Allegations:
Rose criticizes regulatory agencies and Pfizer, pointing out that early regulatory documents (such as the EMA Rolling Review Report) omitted or failed to properly annotate the SV40 components on the plasmid map.
The document claims that speed and profit were prioritized over scientific transparency and safety checks.
Critique of Pandemic "Countermeasures":
The author asserts that the response to COVID-19 functioned less like genuine biodefense and more like an unregulated exercise in biowarfare or corporate profit.
Concerns are raised regarding adverse event reports in pharmacovigilance databases (e.g., VAERS) and the precedent set by using "plug-and-play" mRNA platforms without traditional long-term clinical trials.
Call for Oversight and Governance:
While not opposing synthetic biology outright, the author calls for an immediate global ban on Gain-of-Function (GOF) research and demands strict, open, and independent ethical oversight for synthetic biology, recombination techniques, and AI-driven pathogen research.
Ralph Baric’s 2007 paper stands as a foundational reference in synthetic viral genomics, demonstrating how a SARS-like coronavirus could be de novo assembled from published sequence data alone. Framed as a risk assessment for synthetic biology in the context of biodefense, the paper provides a detailed technical roadmap for constructing infectious chimeric coronaviruses using seamless reverse-genetics techniques. This work exemplifies dual-use (civilian + military) research of concern: the very same tools developed for pandemic preparedness and biodefense can be readily applied to engineer viruses with enhanced pathogenicity, transmissibility, or immune evasion.
With the unexpected discovery of SV40 promoter-enhancer-origin sequences in the Pfizer COVID-19 mRNA injectable products, it becomes apparent how biodefense can become bioterrorism very quickly. These powerful mammalian regulatory elements, retained from a standard pcDNA3.1-type production plasmid, were never intended for human administration. Their detection in commercial vials links a synthetic biology framework directly to the manufacturing process of the “countermeasures” themselves - turning a theoretical dual-use discussion into a concrete, real-world example of how synthetic tools and legacy genetic elements entered hundreds of millions of people under the banner of biodefense.
Short summary of paper
Ralph S. Baric’s 2006 paper entitled: “Synthetic Viral Genomics: Risks and Benefits for Science and Society”1 reviews how synthetic genomics and reverse genetics has transformed virology, both for good and ill. It details the Baltimore classification of viruses and explains established reverse-genetics techniques → from infectious cDNA clones and bacterial artificial chromosome (BAC) vectors for large DNA viruses, to seamless assembly methods (ie: “No See’m2” sites using type IIS restriction enzymes) for RNA viruses like coronaviruses.
These tools have already enabled resurrection of extinct pathogens (ie: 1918 influenza) and construction of chimeric viruses, allowing precise manipulation of virulence, transmissibility, host range and immune evasion genes. Baric catalogs select agents across virus families, noting which are synthesizable from published sequences, and highlights barriers like sequence accuracy, genome stability in bacteria, and technical expertise - barriers he predicted would erode rapidly as DNA synthesis became cheaper and more accessible.
If you read the paper, you will have seen that it provides a detailed, practical framework for de novo synthesis and reverse genetics of SARS-CoV specifically, including seamless full-genome assembly, in vitro transcription to RNA, and recovery of infectious virus. The paper repeatedly notes that synthetic genomics allows reconstruction of viruses like SARS-CoV from sequence data alone, without needing the natural virus, and discusses how this could be used for both ‘legitimate’ research (vaccines, pathogenesis studies) and misuse.
In addition, the methods Baric outlines in the paper are directly applicable to SARS-CoV-2 (also ~30 kb), which is even more clearly laid out in Peter Daszak’s DEFUSE proposal: a collaborative how-to guide for “defusing bat-borne coronaviruses” (Figure 1). Post 2019 implementations have used yeast recombination, Gibson assembly, or similar seamless techniques, but the core principles (synthetic DNA fragments → full-length cDNA → RNA transcripts → infectious virus) are the same. As mentioned, Baric’s lab and collaborators had already demonstrated this for the original SARS-CoV in 2003.3
Figure 1: Project DEFUSE: Defusing the threat of Bat-Borne Coronaviruses. https://drasticresearch.org/wp-content/uploads/2021/09/main-document-preempt-volume-1-no-ess-hr00118s0017-ecohealth-alliance.pdf.
The COVID con: Biodefense or Biowarfare?
The paper is eerily prescient in terms of laying out the infrastructure for both “pandemic preparedness” and “dual-use” procedures. Synthetic approaches enabled rapid response: once a new pathogen’s sequence is known, genes or full genomes can be synthesized for diagnostics, vaccines and therapeutics, without waiting for natural isolates. This paradigm was used during SARS-CoV-2. We are all familiar with it. Considering the enormous damages done - not by the virus but by human-imposed “countermeasures”, this doesn’t seem like defense to me and it all leads back to Baric.4
As part of the COVID “countermeasures”, it very clear from pharmacovigilance data that the nucleoside modified RNA-LNP injections lead to millions of injuries deaths world-wide which to this day, are still not acknowledged by the “authorities”. In the U.S. VAERS domestic data alone for 2021, there are over ten thousand deaths reported in the context of the COVID-19 injectable products, and these absolute counts do not consider under-reporting. If one considers the Foreign death reports in VAERS, this number rises to almost 40,000. Again, these are only the reports that were successfully filed to a single pharmacovigilance system.
Figure 2: Chart showing absolute counts of VAERS domestic death reports from 2016 to 2026. https://vaers.hhs.gov
Worse even, now that the “safe and effective” COVID-19 injectable products that use the nucleoside modified RNA-LNP platform has been green-lighted - in fact forced through the laughable safety checks and balances for the purposes of emergency use due to the “SARS-2 pandemic” - no one intending to use this platform for future injectable products will be required to undergo safety checks via “gold standard” randomized controlled trials (RCTs). In other words, anyone will be able to swap out the spike gene for any gene to produce a new “vaccine” (plug-n-play), and they won’t have to run their new product through any decent clinical trials. And I would bet that even if some form of safety testing is required, the control will be either the Moderna or Pfizer COVID products.
This doesn’t feel like biodefense to me. It sounds like biowarfare on civilians. No one should be threatened with job loss if they don’t allow themselves to be repeatedly injected with an experimental technology for a virus with an infection fatality rate of 0.5678
If anyone would like to defend the “biodefense” idea, please explain to me what exactly is being defended.
Another way to look at this is from the vantage point of thresholds. How much is enough? Development of new synthetics lowers barriers for both bioterrorists, and nowadays, for AIs. With the ability to create/order DNA fragments, assemble “designer” pathogens with enhanced virulence or altered antigenicity, or resurrect ancient strains, without proper regulation, we stand to lose much more than our freedom if this continues under the singular control of what can only be called bioterrorists, in my opinion. Assume the worst, hope for the best.
So what’s the answer? Do we outlaw recombinant technology and synthetic biology development?
The truth of the matter is that I am not fundamentally opposed to synthetic biology. However, because this field carries such profound inherent risks, particularly when its development and application are controlled by clandestine, opaque or unaccountable entities, its continuance does warrant scrutiny. The history of dual-use research demonstrates that without robust transparency and non-conflicted independent oversight, these technologies can be misused with catastrophic consequences. Recombination techniques and synthetic biology need to be safeguarded by open, accountable institutions with strong ethical governance and public scrutiny if they are to continue responsibly, especially in the context of AIs.
You can also ask yourself: What’s worse? Viruses running their course as they always have, or financial-maniac-backed clandestine groups (potentially abusing AIs) making new viruses and “vaccines” that have the potential to wipe us all out all in the name of “public health” whilst calling it biodefense? I, personally, would vote for the former.
Gain-of-function (GOF) research in the most explicit example of the dangers inherent in what some might call biodefense and “scientific progress”. I am not one of those “some”, FYI. GOF research needs to be banned world-wide, in my opinion. “Countermeasures” (gene-based therapies) and the potential for misuse or accidental release of humanized viruses are among just a couple of the potential abuse applications of synthetic biology and recombination techniques. It is important to note that the enabling of humanization of zoonotic viruses complicates and confounds attribution in that synthetic viruses can mimic natural ones exactly. The ultimate whodunnit, eh? Poor pangolins. Thank goodness for endonuclease fingerprints and PRRAR sites to help us suss that out.9
N.B on fear
I thought I would mention that in Baric’s 2007 paper he uses the word “fear” in the very first sentence, and then once more in the introduction in section A. He uses the word “fear” a total of 7 times in this 73 page paper when speaking of viral disease outbreaks and biological warfare.
Figure 3: First page from Synthetic Viral Genomics: Risks and Benefits for Science and Society. Ralph S. Baric, 2007.
Interesting that. He’s not wrong. Fear is the ultimate weapon: you can make people do almost anything if you abuse it.
SV40 - past and present
I would like to call your attention now to a quote on page 41 of Baric’s paper where there is mention of SV40 and its role in virology research and synthetic biology.
In the late 1970’s, a simple observation altered the course of virology research globally. Using a small dsDNA virus genome as a model (the Group I polyomavirus SV40) researchers cloned the viral genome into a bacterial plasmid and propagated the viral genome in bacteria. (page 41)
As a result of this work in the 70s, the pSV2 series was developed by Richard Mulligan and Paul Berg in the early 1980s.1011 SV40 was harnessed not for its ability to cause viral infection, but for its compact, powerful regulatory toolkit that reliably functioned across mammalian hosts where bacterial or weak cellular promoters frequently failed.
The SV40 insert typically includes the SV40 origin of replication (ori), the early promoter, the two 72-bp enhancer repeats (the key strong transcriptional enhancer element), and three 21-bp GC-rich repeats to drive efficient transcription, splicing, polyadenylation, and - in some cases - replication of foreign genes (such as the bacterial selectable markers gpt, neo, or DHFR) in a wide range of mammalian cells.
Current published work demonstrates that there are elements of SV40 (promoter/enhancer/ori) in the Pfizer COVID shots.12 In addition, Kevin McKernan specifically wrote on the existence of a dual copy 72-bp SV40 promoter in the Pfizer COVID shots tested.13
The SV40 promoter-ori DNA consists of a 17-bp A-T-rich sequence, three copies of a G-C-rich 21-bp repeat, and two copies of a 72-bp repeat.
The 21-bp GC-rich repeats were also found in the COVID-19 mRNA injectable products by Wang et al. in 2024.14
The reason these SV40 elements are in the Pfizer vials is because of the plasmid Pfizer intentionally selected for manufacturing the nucleoside modified RNA.
Pfizer’s plasmid is a derivative of pcDNA3.1, which is a shuttle vector capable of both bacterial and mammalian replication via SV40 origins of replication, SV40 enhancers, SV40 promoters and SV40 polyA signals. [6]
Pfizer switched from Process 1 (PCR-amplified linear DNA template) used in the original clinical trials to Process 2 (plasmid-based) for commercial-scale manufacturing. In Process 2, the DNA template was produced using this plasmid grown in E. coli. This plasmid is a derivative of the common pcDNA3.1 mammalian expression vector and contains an SV40 promoter/enhancer/origin (ori) cassette. The SV40 promoter-enhancer primarily drives expression of the KanR/NeoR (aminoglycoside phosphotransferase) selectable marker gene. This enables efficient selection of E. coli bacteria that have successfully taken up the plasmid during cloning and large-scale propagation.
However, the SV40 promoter is a eukaryotic (mammalian-active) element and is not required or optimized for driving KanR expression in bacteria; bacterial selection relies on the gene’s functionality in E. coli, often supported by other backbone elements. Thus, the SV40 cassette is “merely” a legacy feature retained from the pcDNA3.1 vector architecture, which was originally designed for mammalian cell expression and selection (where the SV40 promoter is highly effective for the NeoR marker).
These elements serve purely as manufacturing tools and were never intended for administration to humans.
Why did Pfizer choose this plasmid?
Pfizer retained the full standard backbone rather than re-engineering it to remove these potentially harmful elements. Re-engineering it would have required redesigning and rebuilding the entire plasmid backbone, re-cloning the spike gene into the new backbone, and full re-validation of the manufacturing process.
Time and money lost. Can’t let Moderna win; there are stocks to protect!
Think about this.
Pfizer (or their contract manufacturer) deliberately chose a standard pcDNA3.1-type plasmid containing the SV40 promoter-enhancer-ori cassette as the DNA template for their nucleoside-modified mRNA production. While other vector designs without SV40 elements were available - as demonstrated by Moderna - Pfizer opted for the pre-existing commercial backbone. This choice prioritized speed and scalability during the intense race to market. However, it also resulted in residual plasmid DNA (including SV40 sequences) in the final product at high levels. [11,13]15161718 RNA:DNA hybrids, which are known19 [10] by-products of in vitro transcription are resistant to DNase I enzymatic removal, so why was this enzyme selected during the manufacturing process to “clean out” the DNA?20 And why was the final product - containing high levels of DNA - not reported as such? Why were the detection methods for RNA and DNA “cherry-picked”?2122
And if Pfizer simply didn’t want to waste time and money on producing safe products - even if we are to assume that they believed that it wouldn’t become a problem - why was the plasmid disclosed by Pfizer in the Rolling Rapporteur Review by the EMA not annotated properly? In a formal, high-stakes regulatory document like the EMA Rolling Review Report (November 2020), the plasmid should have been properly and fully annotated. The omission of the SV40 promoter/enhancer-ori on the pST4-1525 map and description has yet to be explained properly and it goes without saying that it was not scientifically rigorous by normal publication standards to omit these SV40 components.
Figure 4: Slide from presentation “Problems and harms associated with novel LNP prophylactic injection methodologies” to Japanese Parliament members. September 2024. Jessica Rose
Figure 5: European Medicines Agency. Rapporteur Rolling Review critical assessment report. Quality aspects. COVID-19 mRNA Vaccine BioNTech. EMEA/H/C/005735/RR/xxx. 19 November 2020.
The plasmid map and description should have been fully annotated, with the SV40 region clearly labeled along with all plasmid components, even if they were considered “standard, non-critical vector backbone components”.
In a critical regulatory filing for a product injected into hundreds of millions of people, it is unacceptable by strict scientific standards to not annotate the plasmid map. The fact that the SV40 components were omitted does not simply reflect rushed emergency processes, an over-reliance on “standard vector” assumptions, and a regulatory culture that sometimes prioritizes speed and high-level summaries over exhaustive detail, it reflects fraud because these annotations appear to have been deliberately removed.
Interestingly, according to Grok, the version of the Rapporteur Rolling Review critical assessment report (EMEA/H/C/005735/RR/xxx, dated 19 November 2020) that contains Figure S.2.3-1 - pST4-1525 Plasmid Map - is part of internal/leaked rolling review documents from an EMA cyber incident,23 and for this reason, is unobtainable for download online. Really. REALLY?
Good thing I saved it before they did the scrub down. Here. You can have it too.
Rapporteurs Rolling Review Report Quality Covid 19 Mrna Vaccine Biontec
16.2MB ∙ PDF file
Again, these plasmids or their component parts were never intended for direct administration to humans. Even a lone SV40 promoter fragment is like a powerful car accelerator pedal floating around without an engine - mostly harmless on its own, but if it accidentally wires itself into your DNA dashboard in the wrong spot, it could rev the wrong genes and potentially contribute to problems like uncontrolled cell growth (aka: cancer). And I don’t have to remind anyone that these products were injected several times in some cases, into billions of people. How many genes have been revved wrong?
Final thoughts
The convergence of Ralph Baric’s detailed roadmap for synthetic coronavirus assembly,24 the documented presence of residual plasmid DNA containing the SV40 promoter-enhancer-origin cassette in Pfizer’s mRNA product, and the unprecedented regulatory shortcuts and omissions surrounding its manufacture raise profound and unanswered questions about the true nature of the COVID-19 response. What was presented as biodefense and pandemic preparedness appears, in critical aspects, to have functioned as an exercise in biowarfare - directed not by a virus, but by human decisions that prioritized speed, profit, and platform expansion over rigorous safety, transparency, and informed consent.
The insertion of powerful mammalian regulatory elements never intended for human administration, combined with the removal of normal clinical trial requirements for future plug-and-play products, demands immediate, independent and transparent investigation. Until these issues are rigorously examined - without institutional protection or narrative control - public trust cannot be restored, and the risks of synthetic biology will continue to outweigh any promised benefits.
Nature abhors both a vacuum and reckless synthetic manipulation.
For more than 50 years, the federal government shamelessly pretended that marijuana had no recognized medical use. Last December 18, President Trump signed an executive order entitled, “Increasing Medical Marijuana and Cannabidiol Research.” Trump ordered the Attorney General and the Drug Enforcement Administration to speed up rule-making to finally enable far more medical research on the benefits of marijuana.
On April 23, Acting Attorney General Todd Blanche announced that henceforth all “FDA-approved marijuana-derived products” and “State-licensed medical marijuana products” are immediately shifted from Schedule 1 to Schedule 3, a far less restrictive federal regulatory regime.
Of course, libertarians want to see all federal restrictions on marijuana abolished. The nearly 100-year federal war on the loco weed has been a disgrace and a failure from the start.
But the long history of federal persecution of marijuana users, researchers, and growers provides a high-potency kick on the perils of federal intervention to purportedly protect Americans’ health.
During the 1920s, the U.S. Department of Agriculture encouraged farmers to grow cannabis to boost their sagging incomes (hemp was used for such things as paper and rope). Marijuana also grew in popularity during the 1920s as a result of Prohibition, which inflated the price of alcohol by curtailing its availability.
During the Great Depression, Mexican immigrants surged into the United States searching for work and brought marijuana with them. Hostility toward the immigrants led to the Marijuana Tax Act of 1937, which effectively criminalized the possession of marijuana and, according to Yale professor David Musto, “mostly put a lot of jazz bands in jail.”
Criminalizing marijuana
Harvard Professor of Psychiatry Lesther Grinspoon notes, “Between 1839 and 1900, more than a hundred articles on the therapeutic uses of marijuana appeared in scientific journals. As late as 1937, extract of cannabis was still a legitimate medicine marketed by drug companies.” The American Medical Association testified at hearings that year urging that marijuana not be effectively banned. Unfortunately, Congress — bowing to the exhortations of the Federal Bureau of Narcotics — proclaimed in 1937 that marijuana had no medical value. Congress effectively prohibited any use of marijuana for ailing Americans. But simply because a majority of congressmen say something doesn’t make it true.
In 1972, the National Organization for the Reform of Marijuana Laws (NORML) petitioned the federal Bureau of Narcotics and Dangerous Drugs to reclassify marijuana and recognize its medical uses. The director of the agency refused to consider the petition. NORML took the case to a federal appeals court, which issued a ruling that admonished the agency for rejecting the petition without “a reflective consideration and analysis.”
In 1975, NORML sued the Drug Enforcement Administration (the successor agency to the Bureau) to force the agency to evaluate the evidence on whether Americans should have access to marijuana strictly for medicinal purposes. DEA held a hearing, and a DEA administrative law judge found some merit on some of NORML’s positions. But the chief of the DEA overturned those aspects of the judge’s decision.
In 1977, a federal court of appeals criticized the DEA’s final order and ordered the agency to reconsider the evidence for the medical benefits of marijuana.
In 1982, NORML petitioned the federal appeals court to force the DEA to follow the court’s previous orders. That same year, the National Academy of Science’s Institute of Medicine concluded: “Cannabis and its derivatives have shown promise in the treatment of a variety of disorders, [including] glaucoma, asthma, … and in the nausea and vomiting of cancer chemotherapy.”
In 1986, a DEA administrative law judge launched an extensive evaluation of the evidence for marijuana. DEA judge Francis Young spent two years conducting hearings and listening to scores of expert witnesses. Young ruled in 1988: “The marijuana plant is anything but a new drug…. Uncontroverted evidence in this record indicates that marijuana was being used therapeutically by mankind 2,000 years before the birth of Christ. The evidence in this record clearly shows that marijuana has been accepted as capable of relieving the distress of great numbers of very ill people and doing so with safety under medical supervision. It would be unreasonable, arbitrary and capricious for a DEA to continue to stand between those sufferers and the benefits of this substance in the light of the evidence of this record.”
How did the DEA respond to the evidence? DEA administrator John Lawn denounced the judge’s finding as a “cruel and dangerous hoax” and refused to accept the judge’s ruling. Lawn announced that the agency would only allow medical use of marijuana if it had already “currently accepted medical use.” And since DEA forbid any doctors from prescribing marijuana for medical use, that somehow meant that the agency must continue to ban its use in the future.
NORML sued again, appealing to a federal court to force the DEA to accept the recommendations of its own administrative law judge, and the court again compelled the DEA to reexamine the issue.
In March 1992, the DEA “reconsidered” and announced that it was right all along and that it would continue to ban any medical use of marijuana. DEA chief Robert Bonner decreed: “Lay testimonials, impressions of physicians, isolated case studies, random clinical experience, reports so lacking in details they cannot be scientifically evaluated and all other forms of anecdotal proof are entirely irrelevant.” Bonner got warmed up and showed some of the fervor that is the pride of DEA: “Beyond doubt, the claims that marijuana is medicine are false, dangerous and cruel. Sick men, women and children can be fooled by these claims and experiment with the drug. Instead of being helped, they risk serious side effects.” Bonner acknowledged that he based his findings on the same testimony and documents that led DEA Administrative Law Judge Young to an opposite conclusion four years earlier.
As Harvard psychiatry professors Lester Grinspoon and James Bakalar noted at that time, “The Government’s real concern is not that marijuana is ineffective as a medicine, but that it is too effective. The Government cannot acknowledge any of this because it has vastly exaggerated the dangers of marijuana for more than 50 years and is still committed to its war against the drug.”
California’s Proposition 215
Clinton’s drug czar General Barry McCaffrey effectively claimed to be a wiser scientist than all the experts who researched marijuana’s effects. On August 15, 1996, while campaigning in California against Proposition 215, which would have legalized the medical use of marijuana, McCaffrey declared: “There is not a shred of scientific evidence that shows that smoked marijuana is useful or needed. This is not science. This is not medicine. This is a cruel hoax.” On December 30, 1996, when asked by a CNN reporter “is there any evidence … that marijuana is useful in a medical situation?” McCaffrey responded: “No, none at all. There are hundreds of studies that indicate that it isn’t.” McCaffrey ridiculed claims of marijuana’s benefit as “Cheech ‘n’ Chong medicine.”
After voters passed the proposition, the drug czar’s office put out a press release warning: “The passage of [Proposition 215] creates a significant threat to the drug control system that protects our children…. The decision to bring appropriate criminal or administrative enforcement action will be, as always, decided on a case-by-case basis.” McCaffrey’s warning sparked a vision of a DEA agent lurking underneath the desk of every doctor.
Federal judge Fern Smith issued a preliminary injunction on April 30, 1997, prohibiting the feds from punishing doctors: “The government’s fear that frank dialogue between physicians and patients about medical marijuana might foster drug use … does not justify infringing the First Amendment…. [T]his case is about the ability of doctors, on an individualized basis, to give advice and recommendations to bona fide patients suffering from serious, debilitating illnesses regarding the possible benefits of personal, medical use of small quantities of marijuana.”
Clinton administration officials sneered at marijuana referendum results. Attorney General Janet Reno declared: “I don’t think that the determination as to whether there is a medical, a scientific medical use of marijuana, should be made at the ballot box. I think it should be made in an informed way after appropriate scientific evaluation.” And if government officials chose to ignore all the scientific evidence, then that was merely political science.
Pressure toward reform
The federal government in 1978 began a program providing marijuana directly to a small number of people with illnesses that undeniably benefited from consuming marijuana, such as glaucoma and epilepsy. But the George H.W. Bush administration closed the program to any new entrants in 1992 after only eight people were certified — even though hundreds of thousands of people suffered from the same illnesses. The Clinton administration refused to reopen the program to new sufferers. The Justice Department, in a 1999 brief, declared: “It became clear that the potential widespread use of marijuana for ‘medical’ purposes under the program … was bad public policy.” According to the Justice Department, the first requisite of good public policy is to pretend that individual citizens do not exist.
In 1997, the CBS situation comedy Murphy Brown featured star Candice Bergen suffering from the aftereffects of chemotherapy. A friend provided her with some marijuana. DEA chief Thomas Constantine denounced CBS for “doing a great disservice” by “trivializing drug abuse” and “pandering to the libertarian supporters of an `open society’ and to the myths of legalization.” Constantine barked: “I am extremely troubled that at a time when teenage drug abuse is doubling … a television show of the caliber of Murphy Brown would portray marijuana as medicine. It is not medicine…. More dangerously, the show sends the message to our children that marijuana must be OK because it’s medicine.” Constantine promised to investigate “if any laws were broken” by broadcasting that show.
Clinton’s drug policy was haunted by the specter of emaciated chemotherapy patients desperately needing something to stop their vomiting and fire their appetites. And nothing works better for this than smoking marijuana. The feds approved pills with THC, the active ingredient in marijuana; however, pills are scant help to someone heaving their guts.
Bluster from Washington political hacks failed to stop the cascade of new scientific evidence on the medicinal benefits of marijuana:
A 1997 study performed on animals at the University of California at San Francisco found that cannabinoids (the active ingredient in marijuana) can be an effective reliever of pain without the adverse side effects of opiates.
The American Journal of Psychiatry reported in 1999 that German researchers successfully used the major psychoactive ingredient in marijuana to treat Tourette’s Syndrome (a complex neuropsychiatric disorder characterized by sudden spasms).
The Proceedings of the National Academy of Sciences reported in 1998 that marijuana may protect brain cells during a stroke.
British researchers revealed in 2000 that a marijuana compound was very effective in helping control the muscle spasms that afflict people with multiple sclerosis.
Clinton administration officials suppressed research results of United Nations affiliates that embarrassed the U.S. drug war. The World Health Organization (WHO) completed a major study of marijuana’s effects in 1997. The draft of the final report included a comparison of the adverse effects of cannabis with alcohol and tobacco. However, the WHO, bowing to pressure from the U.S. government and other drug warriors, suppressed that chapter. New Scientist, a British magazine, acquired a copy of the study and reported that in five out of seven categories of long-term health damage, alcohol was judged more harmful than marijuana. The report also observed that “in developed societies, cannabis appears to play little role in injuries caused by violence, as does alcohol.”
Obama’s prosecutions
In 2008, Democratic presidential candidate Barack Obama appeared to pledge an end to the persecution of medical marijuana users and providers: “What I’m not going to be doing is using Justice Department resources to try to circumvent state laws on this issue.” Regardless, the Obama administration brought almost twice as many prosecutions against medical marijuana providers and users as did the George W. Bush administration. Rob Kampia, executive director of the Marijuana Policy Project, complained in 2012 that “Obama has become more hostile to medical marijuana patients than any president in U.S. history.” A 2012 Time magazine analysis noted that the DEA “has made it clear that medical marijuana is not medicine, and even called it a ‘mortal danger.’”
Obama’s repression of medical marijuana coincided with an explosion in abuse of prescription painkillers. A 2016 federal report estimated that 38 percent of adults had used prescription painkillers in the previous year, resulting in 19,000 deaths (more than the national homicide total). Medical marijuana is a proven pain killer, but the Obama administration (supported by pharmaceutical companies’ campaign contributions and lobbying) scorned it. The National Institute on Drug Abuse torpedoed a 2011 research project testing whether “marijuana helps combat veterans with their post-traumatic stress disorder.”
“When you mix politics and science, you get politics,” observed historian John Barry. Generations of politicians and bureaucrats were willing to scorn scientific research to score “tough on crime” points. The ruling class was perpetually more interested in controlling Americans than in permitting citizens to find relief for all that ailed them. Anyone with an illness or malady that marijuana could help became merely collateral damage in the war on drugs. But as historian Thomas Macaulay observed in 1839, “It is mere foolish cruelty to provide penalties which torment the criminal without preventing the crime.”
James Bovard is a policy adviser to The Future of Freedom Foundation. He is a USA Today columnist and has written for The New York Times, The Wall Street Journal, The Washington Post, New Republic, Reader’s Digest, Playboy, American Spectator, Investors Business Daily, and many other publications. His new book is Last Rights: The Death of American Liberty (2023). He is also the author of Freedom Frauds: Hard Lessons in American Liberty (2017, published by FFF); Public Policy Hooligan (2012); Attention Deficit Democracy (2006); The Bush Betrayal (2004); Terrorism and Tyranny (2003); Feeling Your Pain (2000); Freedom in Chains (1999); Shakedown (1995); Lost Rights (1994); The Fair Trade Fraud (1991); and The Farm Fiasco (1989). He was the 1995 co-recipient of the Thomas Szasz Award for Civil Liberties work, awarded by the Center for Independent Thought, and the recipient of the 1996 Freedom Fund Award from the Firearms Civil Rights Defense Fund of the National Rifle Association. His book Lost Rights received the Mencken Award as Book of the Year from the Free Press Association. His Terrorism and Tyranny won Laissez Faire Book’s Lysander Spooner award for the Best Book on Liberty in 2003. Read his blog. Send him email.